David Bredt, Chief Scientific Officer: Rapport Therapeutics RAPP Sell · Filed 01/16

Trade details

Type: Insider sale
Amount: $222,689
Shares · price: 8,300 sh · $26.83 a share
Held after: 395,775 sh
Stock: Rapport Therapeutics RAPP
Person: David BredtChief Scientific Officer
Trade date: 26/01/15
Filed: 26/01/16
Days to filing: 1 days

Sold 2.1% of holdings

Share of holding sold: 2.1%

Rapport Therapeutics trades, last 26 weeks

What else happened in Rapport Therapeutics around then

Filed or reported within 30 days of the trade day · 25/12/16~02/14

David Bredt's recent trades

David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$156.3K
5,400 sh
$156.3K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$65.1K
2,200 sh
$65.1K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$25.2K
900 sh
$25.2K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$5,480
200 sh
$5,480
Filed 01/16
Traded 01/15
David BredtChief Scientific Officer
Planned sale10b5-1 planRapport Therapeutics
Planned sale10b5-1 plan
Rapport Therapeutics
RAPP
$466.1K
17,000 sh
$466.1K
Filed 01/15
Traded 01/15